Avalyn Pharma (NASDAQ:AVLN – Get Free Report) was upgraded by investment analysts at Zacks Research to a “hold” rating in a research note issued on Wednesday,Zacks.com reports.
AVLN has been the subject of a number of other reports. Wall Street Zen raised Avalyn Pharma to a “hold” rating in a report on Saturday, May 9th. Evercore began coverage on Avalyn Pharma in a report on Tuesday. They issued an “outperform” rating and a $51.00 target price for the company. Guggenheim began coverage on Avalyn Pharma in a report on Monday. They issued a “buy” rating and a $80.00 target price for the company. Jefferies Financial Group began coverage on Avalyn Pharma in a report on Monday. They issued a “buy” rating and a $52.00 target price for the company. Finally, Morgan Stanley began coverage on Avalyn Pharma in a report on Tuesday. They issued an “overweight” rating and a $53.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $59.00.
Check Out Our Latest Stock Analysis on AVLN
Avalyn Pharma Trading Up 5.9%
Insider Buying and Selling
In related news, major shareholder Sr One Capital Management, Llc bought 555,555 shares of the company’s stock in a transaction dated Friday, May 1st. The stock was acquired at an average cost of $18.00 per share, with a total value of $9,999,990.00. Following the acquisition, the insider owned 2,186,562 shares in the company, valued at approximately $39,358,116. This represents a 34.06% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Jill Carroll bought 277,778 shares of the company’s stock in a transaction dated Friday, May 1st. The stock was bought at an average cost of $18.00 per share, with a total value of $5,000,004.00. Following the completion of the acquisition, the director owned 2,186,562 shares in the company, valued at $39,358,116. This represents a 14.55% increase in their position. The SEC filing for this purchase provides additional information.
About Avalyn Pharma
We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.
Read More
- Five stocks we like better than Avalyn Pharma
- 3 Stocks Rallying on Micron’s Price Boost: Substance or Hype?
- Snowflake and the Snowballing Impact of its AI Flywheel
- AI’s Biggest Bottleneck Could Make These 2 Stocks Soar
- These 3 Beaten-Down Stocks Just Saw $25 Million in Insider Buying
Receive News & Ratings for Avalyn Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalyn Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
